Lynparza Combo Recommended by EU Committee as First-line Maintenance for Advanced Ovarian Cancer
News
Lynparza (olaparib), in combination with bevacizumab, has been recommended for approval in the European Union (EU) as a first-line maintenance therapy for women with advanced ovarian cancer positive for homologous recombination deficiency (HRD) and who ... Read more